Mergers & Acquisitions ·
Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, following a Nasdaq…
SGMOSangamo Therapeutics, Inc
Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, following a Nasdaq delisting. The company entered into two stalking horse asset purchase agreements: one with Eli Lilly and Company for $50 million to acquire its technology platforms, and another with Astellas Pharma Inc. for up to $50 million to acquire its Fabry Disease product candidate. Additionally, the company is restructuring its workforce by eliminating approximately 51 roles, representing 40% of its staff, with expected incremental expenses between $3.0 million and $4.0 million. Sangamo Therapeutics, Inc. is a biotechnology company focused on developing gene therapy platforms and programs.